Isradipine: An Update of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Treatment of Mild to Moderate Hypertension

Drugs

Volumn 49, Issue 4, 1995, Pages 618-649

  Brogden, Rex N ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BOPINDOLOL; CAPTOPRIL; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; METHYLDOPA; METOLAZONE; METOPROLOL; NIFEDIPINE; NITROPRUSSIDE SODIUM; PRAZOSIN;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; EDEMA; ESSENTIAL HYPERTENSION; GLUCOSE METABOLISM; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEMODYNAMICS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIPID METABOLISM; MATERNAL HYPERTENSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SUBLINGUAL DRUG ADMINISTRATION; TACHYCARDIA; THROMBOCYTE; VERTIGO;

CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMICS; HUMAN; HYPERTENSION; ISRADIPINE; POSTOPERATIVE COMPLICATIONS; PREGNANCY; RENAL CIRCULATION;

EID: 0028927151     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199549040-00009     Document Type: Article

References (212)

1. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease
2. A randomized comparative study of the electrophysiological and electrocardiographic effects of isradipine vs verapamil
3. Comparison of the cardiac electrophysiologic effects of isradipine and verapamil in man [abstract no.5]
4. Electrophysiologic properties of isradipine (PN 200-110) in humans
5. PN 200-110, a new calcium antagonist: electrophysiological, inotropic and chronotropic effects in guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta
6. Vascular bed and vasoconstrictor-dependent selectivity of the calcium channel antagonist, PN 200-110
7. Failure of tolerance to develop to the acute renal and splanchnic vasodilator effects of the calcium-blocker PN 200-110 in patients with congestive heart failure
8. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging
9. A review of the short-term benefits of antihypertensive treatment with emphasis on stroke
10. Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients
11. Antiischemic and hemodynamic effects of intravenous isradipine, a new calcium antagonist, in coronary heart disease: a comparative double-blind cross-over study with nifedipine
12. Comparison of negative inotropic and vasodilator effects of isradipine and nifedipine after complete autonomic blockade in ischemic heart disease
13. Effects of the calcium antagonist, isradipine, and nifedipine on resting and exercise haemodynamics and the neurohumoral system in patients with stable chronic angina
14. Cardiovascular effects of isradipine in essential hypertension
15. Fruscio M, Gradnik R, et al. Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients
16. Acute effects of isradipine on angiotensin II responsiveness
17. Effects of sustained-release isradipine on blood pressure and peripheral hemodyamics in hypertensive patients
18. Beneficial effects of the calcium antagonist PN 200-110 in patients with congestive heart failure
19. Hemodynamic study of short- and long-term isradipine treatment in patients with chronic ischaemic congestive heart failure
20. Hemodynamic effects of an intravenous infusion of isradipine in patients with congestive heart failure
21. Isradipine for blood pressure reduction following myocardial revascularization [abstract]
22. Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockade in coronary artery disease
23. Use of isradipine in hypertension following coronary artery bypass surgery
24. Acute hemodynamic effects of intravenous isradipine
25. Influence of input rates on (±)-isradipine heamodynamics and concentration-effect relationship in healthy volunteers
26. Central hemodynamics and brachial artery compliance during therapy with isradipine, a new calcium antagonist
27. Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middleaged men
28. Renal and hemodynamic effects of isradipine in essential hypertension
29. Effect of isradipine on cardiopulmonary baroreflex function, regional blood flow, and vascular responsiveness in hypertensive patients
30. Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease [in German]
31. Comparison of isradipine with nitroprusside for control of blood pressure following myocardial revascularization: effects on hemodymanics, cardiac metabolism, and coronary blood flow
32. Effect of methyldopa and isradipine on fetal heart rate pattern assessed by computerized cardiotocography in human pregnancy
33. Oral isradipine and feto-maternal hemodynamics in hypertensive pregnancy
34. Isradipine, a new calcium antagonist: effects on maternal and fetal hemodynamics
35. Improvement of fetal development in cases of intrauterine growth retardation by the calcium antagonist isradipine [abstract]
36. Maternal and fetal cardiovascular changes after intravenous injections of isradipine to pregnant women
37. Computer analysis of fetal heart rate after treatment with isradipine [abstract]
38. Effects of isradipine, a new calcium antagonist, on maternal cardiovascular system and uterine activity in labour
39. Repetitive natriuresis and blood pressure, long term calcium entry blockade with isradipine
40. Long term effects on blood pressure and renal function
41. Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients
42. Effects of longterm administration of isradipine on renal hemodynamics and sodium metabolism
43. Effects of isradipine on hypertension and renal hemodynamics
44. Long-term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function
45. Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin
46. Attenuation of endothelin effects by a chloride channel inhibitor, indanyloxyacetic acid
47. Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy
48. Isradipine decreases exercise-induced albuminuria in patients with essential hypertension
49. Concomitant administration of isradipine and spirapril prevents reduction of renal function induced by acute administration of spirapril in patients with reduced renal function
50. Effects of isradipine in type 1 (insulin-dependent) diabetic patients with albuminuria and normal blood pressure
51. Combined actions of isradipine and captopril on renal function in hypertension
52. Renal effects of the new calcium channel blocking drug isradipine
53. The effect of isradipine on glycemie control and blood lipids in black patients with type I diabetes
54. Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus
55. Metabolic effects of isradipine as monotherapy or in combination with pindolol during longterm antihypertensive treatment
56. Metabolie, hematological, and cardiac effects of long-term isradipine treatment in mildto-moderate essential hypertension
57. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension
58. Serum lipoprotein profile under different antihypertensive therapy
59. Hungarian isradipine study (HIS): long-term (3 year) effects on blood pressure and plasma lipids
60. Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients
61. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbits by treatment with the calcium blocker PN 200-110
62. Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110
63. Antiatherogenic properties of calcium antagonists: State of the art
64. Structural changes in the endothelium of the femoral artery of spontaneously hypertensive rats: sensitivity to isradipine treatment
65. Effect of chronic dihydropyridine (isradipine) on the large arterial walls of spontaneously hypertensive rats
66. Influence of isradipine treatment on the morphology of the aorta in spontaneously hypertensive rats
67. Effect of long term isradipine treatment on the morphology of the endothelium in the aorta of spontaneously hypertensive rats
68. 125I low density lipoprotein entry in hypercholesterolemic rabbits
69. Aspirin abolishes the decreased low-density lipoprotein (LDL) entry into rabbit arterial wall induced by the calcium channel blocker, isradipine
70. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I effect on progression of atherosclerosis and endothelial dysfunction
71. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II effect on regression of atherosclerosis and restoration of endothelial function
72. Increased beta-thromboglogulin in essential hypertension: Interaction between plasma adrenaline, platelet function and blood lipids
73. Platelet aggregation in hypertension and the effects of antihypertensive treatment
74. Serotonin and platelet activation during treatment with isradipine
75. Effects of isradipine on platelet function in hypertension at rest and during exercise
76. Effects of isradipine sustained release (I-SRO) on platelet functions and fibrinolysis in essential hypertensives with or without other risk factors [abstract]
77. Isradipine improves platelet function in hypertensives
78. Treatment of hypertension with calcium antagonists and aspirin. Effects on 24-H platelet activity
79. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin
80. Effect of isradipine on platelet aggregation and oxygen free radicals in hypertension
81. Isradipine increases platelet-low-density lipoprotein binding: evidence from ex-vivo studies in humans
82. Prognostic complications of echocardiographically determined left ventricualr mass in the Framimgton Heart Study
83. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framington Heart Study
84. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men
85. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
86. Effects of sustained-release isradipine on left ventricular anatomy and function in systemic hypertension
87. Regression of left ventricular hypertrophy with isradipine in previously untreated hypertensive patients
88. Regression of left ventricular hypertrophy in the short-term treatment of hypertension with isradipine
89. Reversal of left ventricular hypertrophy following treatment of hypertension with isradipine
90. Regression of cardiac hypertrophy in hypertensive patients by long-term treatment with isradipine
91. Regression of left ventricular hypertrophy with isradipine antihypertensive therapy
92. Effect of isradipine in Black patients with very severe hypertension. 24-hour ambulatory blood pressure monitoring and echocardiographic evaluation
93. Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension
94. Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril
95. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension
96. Correction of left ventricular ischemia in blacks with hypertensive heart disease
97. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension
98. Clinical pharmacokinetics of isradipine
99. Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man
100. Nitrendipine kinetics in normal and impaired renal function
101. Nifedipine kinetics and bioavaiablitiy after single intravenous and oral doses in normal subjects
102. Calcium antagonists: pharmacokinetic properties
103. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man
104. Pharmacokinetics and metabolism of nifedipine
105. The pharmacokinetics of oral isradipine in normal volunteers
106. Pharmacokinetics and pharmacodynamics of the sustained-release isradipine -a review of studies to date [in German]
107. Bioequivalence od a slow-release and a non-retard formulation of isradipine
108. Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients
109. Reduced bioavailablity of the calcium antagonist isradipine (Lomir Retard) in pregnant patients [abstract 2417]
110. Factors influencing isradipine and amlodipine binding to human plasma lipoproteins
111. Transplacental passage of isradipine in the treatment of pregnancy-induced hypertension
112. The effects of renal function on the disposition of isradipine
113. Pharmacokinetics of isradipine in patients with chronic liver disease
114. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients
115. The pharmacokinetics of isradipine in hypertensive subjects
116. Timing of blood pressure measurements in determining anomalies in duration of effect of an antihypertensive drug: assessment of isradipine
117. Pharmacokinetics-dynamics relationships of isradipine in chronic stable angina patients [abstract]
118. Isradipine doseconfirmation study in Filipino patients with mild to moderate hypertension
119. Dose titration study of isradipine in Chinese patients with mild to moderate essential hypertension
120. Multicentre isradipine dose-confirmation study in Thai patients with hypertension
121. Double-blind multicentre isradipine dose-confirmation study in Pakistan
122. Multicenter evaluation of efficacy, tolerability and safety of a new first-line antihypertensive drug, isradipine, in a Latin-American population
123. Efficacy, tolerability and safety of isradipine (Lomir) in the treatment of mild to moderate Tanzanian hypertensives
124. A comparison of the safety of therapeutically equivalent doses of isradipine and diltiazem for treatment of essential hypertension
125. A multicenter comparison of isradipine and felodipine in the treatment of mildto-moderate hypertension
126. First clinical experience with isradipine in the treatment of hypertension in Portugal
127. Efficacy and tolerance of isradipine and sustained-release nifedipine in the management of hypertension
128. The calcium antagonist isradipine in the therapy of hypertension. A double-blind crossover comparison with nifedipine
129. Amulticenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension
130. A multicenter comparison of isradipine and prazosin for treatment of essential hypertension
131. Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH)
132. Multicenter comparison of once- and twice-daily isradipine to hydrochlorothiazide for the treatment of hypertension in elderly patients
133. A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension
134. Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension
135. Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women
136. Comparison of isradipine and hydrochlorothiazide alone or in combination with enalapril for the treatment of hypertension in black and Indian patients
137. Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study
138. Circadian antihypertensive effects of isradipine retard in patients with essential hypertension in comparison to placebo [in Germany]
139. Isradipine sustained release once daily in the treatment of mild hypertension in the elderly
140. Low-dose isradipine once daily effectively controls 24-H blood pressure in essential hypertension
141. Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring
142. Isradipine: a slow-release formulation given once daily controls blood pressure for 24 H
143. Does isradipine modified release 5 mg once daily reduce blood pressure for 24 hours?
144. A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients
145. Clinical equivalence of once-daily administration of a modified-release formulation of isradipine and twice-daily administration of the standard formulation
146. Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure
147. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomised, parallel-group study
148. Circadian antihypertensive efficacy and tolerability of a slow release isradipine formulation intra-individually compared with nitrendipine [in German]
149. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension
150. Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension
151. Blood pressure lowering effect and adverse events during treatment of arterial hypertension with isradipine and hydrochlorothiazide
152. Isradipine in monotherapy and in combination with bopindolol: results of a 3-month multicentre study in hypertensives
153. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial
154. A multicenter, double-blind, randomized, placebo-controlled study of isradipine and methyldopa as monotherapy or in combination with captopril in the treatment of hypertension. The LOMIR-MCT-IH Research Group
155. Dynamics trial of isradipine in hypertension with and without coexisting diseases
156. Anti-hypertensive efficacy of isradipine as monotherapy or in combination with hydrochlorothiazide in mild to moderate hypertension [abstract]
157. MIS (Multicentric Isradipine Study of antihypertensive therapy)
158. Does the combination of ACE inhibitor and calcium antagonist control hypertension and improve quality of life? The LOMIR-MCT-IL Study experience
159. Effects of antihypertensive medications on quality of life in elderly hypertensive women
160. Isradipine in the treatment of mild-to-moderate hypertension. The Austrian Multicenter Isradipine cum Spirapril Study (AMICUS)
161. Isradipine treatment for hypertension in general practice in Hong Kong
162. Efficacy, safety, and tolerability of isradipine in hypertension as used in general practice in a developing country (Pakistan)
163. Isradipine in the treatment of mild-to-moderate hypertension in Portugal
164. Isradipine in the treatment of mild-to-moderate hypertension in geriatric patients
165. Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society
166. Slow-release oral isradipine in the treatment of essential hypertension
167. Nationwide evaluation of isradipine (Dynacirc) in Filipino patients with essential hypertension. Towards the Rational and Ideal Treatment of Blood Pressure Elevation (TRIBE) Study
168. Long-term (2-year) isradipine data in the treatment of mild-to-moderate hypertension
169. Hypertension following myocardial revascularization: its prevalence and etiology
170. Hypertension after coronary operation: can it be prevented by pusatile flow?
171. Intravenous nifedipine for control of hypertension in patients after coronary artery bypass graft surgery
172. Comparative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary-artery bypass-surgery
173. Isradipine for the treatment of hypertension following coronary artery bypass graft surgery: a randomized trial versus sodium nitroprusside
174. Treatment of postoperative hypertension after coronary artery bypass surgery
175. Isradipine for treatment of acute hypertension after myocardial revascularization
176. Isradipine and the coronary circulation
177. The use of calcium antagonists to treat intra-operative hypertension—evaluation of efficacy and safety of a new dihydropyridine derivative, intravenous isradipine, during abdominal surgery
178. Management of perioperative hypertension using intravenous isradipine
179. Isradipine in the treatment of hypertensive crisis in ambulatory patients
180. Parenteral isradipine reduces blood pressure in hypertensive crisis
181. Hypertension in pregnancy. Correlation with fetal outcome
182. Hypertension in pregnancy: pathophysiology and management
183. Intravenous isradipine in the management of severe hypertension of pregnancy in black patients: a pilot study
184. Snoring as a risk factor for ischaemic heart disease and stroke in men
185. Snoring as a risk factor for disease: an epidemiological survey
186. Is snoring a cause of vascular disease? An epidemiological review
187. Effects of antihypertensive medication on hypertension in patients with sleep apnoea
188. Pathophysiology of cyclosporin A nephrotoxicity
189. Cyclosporin-associated chronic nephropathy
190. Effect of isradipine on cyclosporin A-related hypertension
191. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclertic Therapy (INTACT)
192. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis
193. Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance study
194. A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema
195. Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension
196. A high incidence of cough associated with combination therapy of hypertension with isradipine and lisinopril in Chinese subjects
197. Comparison of isradipine and hydrochlorothiazide in hypertension [abstract]
198. Influence of diltiazem on cyclosporin clearance
199. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients
200. Verapamil inhibits cyclosporin metabolism
201. Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients
202. No clinically significant interaction between ciclosporin and isradipine
203. The beneficial effects of isradipine on renal hemodynamics in cyclosporine-treated renal transplant recipients
204. Lack of effect of isradipine on cyclosporin pharmacokinetics
205. Preservation and restitution of vascular integrity by antihypertensive therapy: do calcium antagonists do more than lower blood pressure